Allergan said on Monday that it has agreed to pay several groups of Loestrin buyers a total of $300 million and will avoid a looming trial over claims that a pair of its subsidiaries delayed generic alternatives to the birth control drug.
A trial was set to commence in Rhode Island federal court on Monday over claims that Warner Chilcott and Watson Pharmaceuticals violated antitrust law through patent settlements and other conduct that allegedly kept competing generic versions of Loestrin off the market.
Allergan said in a statement that the settlement includes no admission of wrongdoing and covers classes of direct and indirect buyers, as well as direct buyers that opted out of the class. The class settlements will need court approval, the company said.
. . .
The end payor class is represented by Hilliard & Shadowen LLP, Miller Law LLC, Motley Rice LLC and Cohen Milstein Sellers & Toll PLLC.
The complete article can be viewed here.